A systematic review and meta-analysis by Dekkers et al. has assessed the effects of dopamine agonist withdrawal in patients with hyperprolactinemia. But not all dopamine agonists are the same, and much depends on the criteria for patient selection and the drug withdrawal strategy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dekkers, O. M. et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. doi:10.1210/jc.2009–1238.
Ben-Jonathan, N. & Hnasko, R. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 22, 724–763 (2001).
Kontogeorgos, G. et al. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol. 111, 46–52 (2006).
Landolt, A. M. & Osterwalder, V. Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J. Clin. Endocrinol. Metab. 58, 1179–1183 (1984).
Stefaneanu, L. et al. Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr. Pathol. 11, 341–352 (2000).
Esiri, M. M., Bevan, J. S., Burke, C. W. & Adams, C. B. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J. Clin. Endocrinol. Metab. 63, 383–388 (1986).
Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006).
Colao, A. et al. Predictors of remission of hyperprolactinemia after long-term withdrawal of cabergoline therapy. Clin. Endocrinol. 67, 426–433 (2007).
Colao, A. et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349, 2023–2033 (2003).
Kharlip, J., Salvatori, R., Yenokyan, G. & Wand, G. S. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94, 2428–2436 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Molitch, M. Can prolactinomas be cured medically?. Nat Rev Endocrinol 6, 186–188 (2010). https://doi.org/10.1038/nrendo.2009.278
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.278
